8-K/A: UnitedHealth Reaffirms 2025 EPS, Updates Medicare Star Ratings

UnitedHealth Group reaffirms its adjusted 2025 earnings per share expectations and provides an update on preliminary Medicare Advantage star ratings.

Summary

• UnitedHealth Group senior leaders will be meeting with investors and analysts between September 8, 2025, and September 10, 2025.
• The company reaffirms its adjusted 2025 earnings per share expectations, which were previously disclosed on July 29, 2025.
• The adjusted EPS outlook incorporates the acquisition of Amedisys, which closed in August 2025 and is expected to be dilutive due to financing costs and integration investments.
• Preliminary Centers for Medicare & Medicaid Services (CMS) Medicare Advantage star ratings for Star Year 2026 / Payment Year 2027 estimate approximately 78% of membership in 4-star or higher plans.
• This preliminary star rating estimate is consistent with the company's expectations and in line with historical performance.

Sentiment

Score: 7

Explanation: The reaffirmation of adjusted EPS guidance and consistent Medicare Advantage star ratings indicate a stable operational and financial outlook. While the Amedisys acquisition is noted as dilutive, this is an expected short-term impact of strategic growth, leading to a generally positive but expected sentiment.

Positives

• Reaffirmation of adjusted 2025 earnings per share expectations suggests stability in the financial outlook.
• Preliminary Medicare Advantage star ratings indicate approximately 78% of membership in 4-star or higher plans, which is consistent with expectations and historical performance, positively impacting future revenue.

Negatives

• The acquisition of Amedisys, which closed in August 2025, is expected to be dilutive to adjusted earnings per share due to financing costs and integration-related investments.

Risks

• Ability to effectively estimate, price for, and manage medical costs.
• New or changes in existing health care laws or regulations, or their enforcement or application.
• Cyberattacks, other privacy/data security incidents, or failure to comply with related regulations.
• Reductions in revenue or delays to cash flows received under government programs.
• Changes in Medicare, the CMS star ratings program, or the application of risk adjustment data validation audits.
• DOJ's legal actions concerning participation in the Medicare program.
• Ability to maintain and achieve improvement in quality scores impacting revenue.
• Failure to maintain effective and efficient information systems or if technology products do not operate as intended.
• Risks and uncertainties associated with businesses providing pharmacy care services.
• Competitive pressures, including ability to maintain or increase market share.
• Changes in or challenges to public sector contract awards.
• Failure to achieve targeted operating cost productivity improvements.
• Failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals, and other service providers.
• Impact of potential changes in tax laws and regulations.
• Increases in costs and other liabilities associated with litigation, government investigations, audits, or reviews.
• Failure to complete, manage, or integrate strategic transactions.
• Risks and uncertainties associated with the sale of remaining operations in South America.
• Risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters, and other extreme events.
• Failure to attract, develop, retain, and manage the succession of key employees and executives.
• Investment portfolio performance.
• Impairment of goodwill and intangible assets.
• Failure to protect proprietary rights to databases, software, and related products.
• Downgrades in credit ratings.
• Ability to obtain sufficient funds from regulated subsidiaries or external financings to fund obligations, reinvest in business, maintain debt to total capital ratio, maintain quarterly dividend, or continue repurchasing shares.

Future Outlook

UnitedHealth Group reaffirms its adjusted 2025 earnings per share expectations, which include the dilutive impact of the Amedisys acquisition. The company also anticipates approximately 78% of its Medicare Advantage membership to be in 4-star or higher plans for Star Year 2026 / Payment Year 2027, aligning with historical performance and expectations.

Management Comments

• Our preliminary review of the information [CMS Star Ratings] estimates we will have approximately 78% of our membership in 4 star or higher plans, which is consistent with our expectations and in line with historical performance.

Industry Context

This announcement provides an update on key operational and financial metrics for a major player in the U.S. healthcare and managed care industry. The reaffirmation of EPS guidance, despite the dilutive effect of an acquisition, suggests a stable financial outlook in a dynamic regulatory and competitive environment. The Medicare Advantage star ratings update is crucial as these ratings directly impact reimbursement levels and market competitiveness within the highly regulated government programs sector.

Comparison to Industry Standards

• The reaffirmation of adjusted EPS guidance, even with acquisition-related dilution, suggests a robust financial management approach, potentially outperforming peers facing similar integration challenges.
• Achieving approximately 78% of Medicare Advantage membership in 4-star or higher plans for Star Year 2026/Payment Year 2027 is a strong indicator of quality and operational efficiency. This level of performance is generally considered competitive within the Medicare Advantage market, where companies like Humana and Elevance Health (formerly Anthem) also strive for high star ratings to maximize revenue and attract members. Specific comparable results would require detailed competitor filings for the same period, but 4-star and above is a benchmark for strong performance.

Stakeholder Impact

• Shareholders: Reaffirmation of EPS guidance and stable star ratings could provide confidence, while acquisition dilution might be a short-term concern.
• Customers (Medicare Advantage members): Consistent high star ratings (78% in 4-star or higher plans) indicate continued quality of service and benefits.
• Employees: Integration of Amedisys implies potential changes and opportunities.
• Regulators (CMS): Ongoing evaluation of star ratings and adherence to program requirements.

Next Steps

• Senior leaders will continue meeting with investors and analysts until September 10, 2025.
• The company will continue to evaluate the preliminary CMS Medicare Advantage star ratings.

Key Dates

Recommendation

The filing indicates a stable outlook with reaffirmed EPS guidance and consistent Medicare Advantage star ratings, which are positive. However, the dilutive impact of the Amedisys acquisition and the extensive list of forward-looking risks suggest that while the company is performing as expected, there are no immediate catalysts for a "buy" recommendation based solely on this filing. A "hold" position allows investors to maintain exposure while monitoring the integration of Amedisys and the realization of future star ratings.

Keywords

UnitedHealth Group, UNH, Earnings Per Share, EPS, Medicare Advantage, CMS Star Ratings, Amedisys Acquisition, Healthcare, Managed Care, Health Insurance, Financial Outlook, Investor Meeting